HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Litigates To Wash Off Sanitizer Ebola Claim, Warns On Colloidal Silver Benefits

This article was originally published in The Rose Sheet

Executive Summary

A complaint filed in federal court in California seeks an order to block Innovative BioDefense from distributing Zylast antiseptic hand sanitizer products that, due to its claims, are unapproved new drugs under FDA regulations. A warning letter to Silver Armor states that drug claims render its Silver Ramon and Natural Health brand products, which contain colloidal silver, unapproved new drugs and that the is noncompliant with supplement GMP regulations.

You may also be interested in...

Soaptronic’s Germstar Antiseptic Rubs Clean On Ingredients, Not On Claims

Claims that Germstar antiseptic cleanser line treat swine flu, E-coli, salmonella and norovirus are not part of an OTC final monograph or TFM, FDA says in warning letter. The products contain active ingredients FDA deferred from OTC monographs for consumer and health care rubs to await additional data.

Supplement GMP Inspections Slowing As FDA Makes 'Potential' Data Useful

FDA doesn't expect o continue increasing GMP inspections at the rate established from fiscal 2013 through 2017, says Cara Welch, assistant director of the office in the agency's Office of Dietary Supplement Programs."We're not going to keep growing at that rate because we have a lot of regulations we have to inspect and we're always resource strapped," she said at a recent industry conference.

Ebola Crisis Causes Drug Claim Symptoms In Products Marketed As Supplements

FTC joins FDA in one of the three warning letters to firms claiming their products can either prevent or treat Ebola.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts